Engimmune Therapeutics
Founded 2021 · 12 employees on LinkedIn · 2 known investors
Find your way into Engimmune Therapeutics
157 people in our graph share verified history with the Engimmune Therapeutics team — schools, employers, funds. One of them is your warm intro.
Tony Nystenunlockedknows Rodrigo Vazquez-Lombardi · together at University of Sydney (overlapped)
×5knows the team · via ETH Zurich
×4knows the team · via University of Sydney
knows the team · via Engimmune Therapeutics
knows the team · via Garvan Institute of Medical Research
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.
Founders & leadership
Engimmune Therapeutics was founded in 2021 by Rodrigo Vazquez-Lombardi and Sai Reddy.
RV
Rodrigo Vazquez-LombardiinRodrigo Vazquez-Lombardi is a protein engineer and immunologist with over a decade of experience developing engineered cancer immunotherapies across antibody, cytokine, and cellular modalities. He is co-founder of Engimmune Therapeutics, which develops soluble TCR therapeutic candidates for oncology and immunotherapy applications.
SR
Sai ReddyinFounder
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeedMay 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Engimmune Therapeutics do?
- Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.
- Who founded Engimmune Therapeutics?
- Engimmune Therapeutics was founded by Rodrigo Vazquez-Lombardi, Sai Reddy in 2021.
- Who are Engimmune Therapeutics's investors?
- Engimmune Therapeutics's investors include Pureos Bioventures, Novo Holdings.